

Galcanezumab Market

Market Report | 2025-05-01 | 271 pages | Datastring Consulting

AVAILABLE LICENSES:

- Multi User License \$1399.00

Report description:

Description

The market, for Galcanezumab was estimated at \$1.3 billion in 2024; and it is anticipated to increase to \$3.5 billion by 2030 with projections indicating a growth to around \$8.1 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 18.4% over the forecast period.

Segmentation

To see report segmentation please view the table of contents, or ask us for samples.

Table of Contents:

Chapter 1: Executive Summary - Major Markets & Their Performance - Statistical Snapshots

Chapter 2: Research Methodology

2.1: Axioms & Postulates

2.2: Market Introduction & Research Methodology - Estimation & Forecast Parameters / Major Databases & Sources

Chapter 3: Market Dynamics

3.1: Market Overview - Drivers / Restraints / Opportunities / M4 Factors

3.2: Market Trends

3.2.1: Introduction & Narratives

3.2.2: Market Trends - Impact Analysis (Short, Medium & Long Term Impacts)

3.3: Supply Chain Analysis

3.4: Porter's Five Forces - Suppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry

Chapter 4: Global Galcanezumab Market Size, Opportunities & Strategic Insights, by Dosage Form

4.1: Pre-filled Syringes

4.2: Auto-injector Devices

Chapter 5: Global Galcanezumab Market Size, Opportunities & Strategic Insights, by Prescriber Types

5.1: Neurologists

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2: Primary Care Physicians
- 5.3: Pain Specialists
- 5.4: Headache Clinics
- Chapter 6: Global Galcanezumab Market Size, Opportunities & Strategic Insights, by End Users
 - 6.1: Hospitals
 - 6.2: Private Clinics
 - 6.3: Research Institutes
 - 6.4: Others
- Chapter 7: Global Galcanezumab Market Size, Opportunities & Strategic Insights, by Therapeutic Application
 - 7.1: Migraines
 - 7.2: Cluster Headaches
- Chapter 8: Global Galcanezumab Market Size, Opportunities & Strategic Insights, by Distribution Channel
 - 8.1: Hospital Pharmacies
 - 8.2: Retail Pharmacies
 - 8.3: Online Pharmacies
- Chapter 9: Galcanezumab Market, by Region
 - 9.1: North America Galcanezumab Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.1.1: U.S.
 - 9.1.2: Canada
 - 9.2: Europe Galcanezumab Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.2.1: Germany
 - 9.2.2: France
 - 9.2.3: UK
 - 9.2.4: Italy
 - 9.2.5: The Netherlands
 - 9.2.6: Rest of EU
 - 9.3: Asia Pacific Galcanezumab Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.3.1: China
 - 9.3.2: Japan
 - 9.3.3: South Korea
 - 9.3.4: India
 - 9.3.5: Australia
 - 9.3.6: Thailand
 - 9.3.7: Rest of APAC
 - 9.4: Middle East & Africa Galcanezumab Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.4.1: Saudi Arabia
 - 9.4.2: United Arab Emirates
 - 9.4.3: South Africa
 - 9.4.4: Rest of MEA
 - 9.5: Latin America Galcanezumab Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.5.1: Brazil
 - 9.5.2: Mexico
 - 9.5.3: Rest of LA
 - 9.6: CIS Galcanezumab Market Size, Opportunities, Key Trends & Strategic Insights
 - 9.6.1: Russia
 - 9.6.2: Rest of CIS
- Chapter 10: Competitive Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1: Competitive Dashboard & Market Share Analysis
- 10.2: Company Profiles (Overview, Financials, Developments, SWOT)
 - 10.2.1: Eli Lilly and Company
 - 10.2.2: Novartis International AG
 - 10.2.3: Teva Pharmaceutical Industries Ltd.
 - 10.2.4: Biohaven Pharmaceutical
 - 10.2.5: Amgen Inc.
 - 10.2.6: Allergan Plc.
 - 10.2.7: GlaxoSmithKline Plc.
 - 10.2.8: Pfizer Inc.
 - 10.2.9: AstraZeneca Plc.
 - 10.2.10: Johnson & Johnson Services Inc.
 - 10.2.11: Sanofi S.A.
 - 10.2.12: Bayer AG.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Galcanezumab Market

Market Report | 2025-05-01 | 271 pages | Datastring Consulting

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Multi User License	\$1399.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-08"/>
		Signature	<div style="border: 1px solid black; height: 60px; width: 100%;"></div>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com